Will be back at JPM healthcare conference the coming Jan after three years. Look forward to reconnecting with old friends and meeting new ones! #JPM23

Congrats to Belief BioMed!

😪😪😪

Congrats to the IPO of our portfolio company Structure Tx! endpts.com/behind-structu…

Congrats to our portfolio company Insilico Medicine for their licensing agreement with Exelixis for ISM3091, a Potentially Best-in-Class USP1 Inhibitor - businesswire.com/news/home/2023…

We are excited to share that Qiming ranked No.5 among top global investors in the Venture Capital Journal VCJ50 2023! The annuaal VCJ 50 evaluates VC firms based on the amount of direct investment capital raised for seed, early, and multi-stage deals, excluding growth deals. #QMawards

Abbisko Therapeutics Obtained Approval from U.S. FDA to Conduct First-in-Human (FIH) Clinical Study of A Next-Generation FGFR4 Mutant Inhibitor ABSK012

9 Nov 2023, Shanghai—Abbisko Therapeutics today announced that ABSK051, a novel small molecule CD73 inhibitor, has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China. #bio #pharma #inhibitor #cancer

A new story in Bloomberg captures Insilico's leading role in #AI drug discovery, as we continue to advance the first fully generative AI drug for #IPF through mid-stage trials with initial results expected early 2025. Kanoko Matsuyama bloomberg.com/news/articles/…

We are officially entering the era of gene editing!

Congrats to Abbisko Therapeutics (SEHK:2256) on the #partnership with Merck! Dr. Xu Yao-chang, Chairman of Abbisko, sees it as a crucial milestone for the global commercialization of pimicotinib and a new model for the company's pipeline. #QMPortfolio #QMHealthcare

The most active (by # of deals) biopharma investors is an interesting list: Many companies will tout RA Capital as a shareholder but remember they are in many deals Alexandria take stakes when companies use their space ARCH writes big checks so keep an eye on them

Exciting news from #QMportfolio Medilink Therapeutcis! They've reached a global collaboration and license agreement with Roche for the development of its ADC candidate YL211 targeting c-Met against solid tumors. linkedin.com/pulse/medilink…

Kicking off #JPM2024 at pre-JPM CTIC 7th Healthcare Summit with a lively panel on the early stage innovation and sharing my insights for 2024 alongside Kan chen Qiming Venture Partners, John Lepore of ProFoundTx & Ricky Sun Bain Capital Life Science moderated by my colleague KT Moortgat

An inspiring evening as we gathered with CEOs of our portfolio companies who attended #JPM24. Innovation in healthcare knows no borders. Qiming will continue to champion innovators who are setting new standards in healthcare and facilitate a worldwide reach. #QMhealthcare

#QMPortfolio OriCell Therapeutics' IND application for OriCAR-017 has been granted by the US FDA. OriCAR-017 is an innovative CAR-T therapy targeting GPRC5D for patients with relapsed/refractory multiple myeloma. The company will gear up to launch clinical development in the US.

28 Feb. 2024, Abbisko presented the preliminary first-in-human results of its next-generation highly selective FGFR2/3 inhibitor ABSK061 in patients with advanced solid tumors during the 2024 European Society for Medical Oncology Targeted Anticancer Therapies Congress ESMO - Eur. Oncology.

Medilink Therapeutics is set to showcase its next-generation #ADC technology platform TMALIN (Tumor Microenvironment Activatable LINker-payload), along with the latest preclinical data on the innovative ADC YL205, for the first time at #AACR 2024.

Congrats to Abbisko Therapeutics for achieving a major milestone! Pimicotinib is an orally available, highly selective and potent small molecule inhibitor of CSF-1R, which received the BTD from China NMPA and FDA, along with the PRIME designation from the EMA.

What even is.... Too crowded? 🤔